Company intelligence / Profile preview

Richwood Pharmaceuticals

Ownership
Private
Development stage
Other
01

Overview

Richwood Pharmaceuticals developed and commercialized prescription and over-the-counter drugs, primarily in pain management and central nervous system disorders. Its flagship product was Adderall, a mixed amphetamine salts formulation for ADHD. The company grew through acquisitions of other pharma manufacturers before being acquired by Shire Group plc in 1997.

Therapeutic areas
PsychiatryNeurology
Modalities
Small molecule
Industry
Biotech

Beyond the preview

Go deeper on Richwood Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Richwood Pharmaceuticals.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call